Clinical trial shows evolocumab reduces cardiovascular event risk by 31% in high-risk diabetes — Evidence Review

People with high-risk diabetes but no diagnosed atherosclerosis experienced a significantly reduced risk of a first major cardiovascular event when treated with evolocumab, according to a new randomized trial published in JAMA. Related studies generally support these findings, showing that intensive LDL cholesterol lowering—including with PCSK9 inhibitors like evolocumab—reduces cardiovascular events in high-risk populations.

• Multiple large randomized controlled trials have demonstrated that evolocumab and other PCSK9 inhibitors significantly lower LDL cholesterol and reduce cardiovascular events, especially in patients with established cardiovascular disease; the current study extends these benefits to a higher-risk primary prevention group without established atherosclerosis 1 2 12.
• Meta-analyses indicate that greater reductions in LDL cholesterol, whether achieved with statins or PCSK9 inhibitors, are associated with a proportional decrease in major vascular events, supporting the strategy of more intensive cholesterol lowering for both primary and secondary prevention 9 10 14.
• While previous studies focused mainly on patients with established cardiovascular disease, this new research highlights the potential role of early and intensive LDL-C lowering in high-risk diabetic patients without significant atherosclerosis, an area where evidence has been limited 6 13.

Study Overview and Key Findings

Cardiovascular disease remains a leading cause of death worldwide, and diabetes significantly increases this risk—even before the development of clinically diagnosed atherosclerosis. Traditionally, aggressive cholesterol-lowering therapies like PCSK9 inhibitors have been reserved for patients with established cardiovascular disease. This study addresses whether earlier intervention with evolocumab, in addition to standard statin therapy, can reduce major cardiovascular events in high-risk diabetic patients who do not yet show evidence of significant atherosclerotic plaque. The findings suggest a shift in preventive strategies may be warranted for this population.

Property	Value
Organization	Mass General Brigham, Amgen Inc.
Journal Name	JAMA
Authors	Nicholas A. Marston, Erin A. Bohula, Jeong-Gun Park, Sabina A. Murphy, Ron Blankstein, Robert P. Giugliano, Marc S. Sabatine, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Emileigh Walsh, Lyrica Liu, Subodh Verma, Naveed Sattar, Stephen J. Nicholls, Jose Lopez-Sendon, Ioanna Gouni-Berthold, Lale Tokgozoglu, Marcoli Cyrille, Gabriel Paiva da Silva Lima
Population	People with high-risk diabetes without significant atherosclerosis
Sample Size	n=3,655
Methods	Randomized Controlled Trial (RCT)
Outcome	Risk of first major cardiovascular event
Results	Evolocumab reduced first major cardiovascular event risk by 31%.

Literature Review: Related Studies

To place these findings in context, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:

1. evolocumab heart attack risk reduction
2. cholesterol drugs cardiovascular event outcomes
3. PCSK9 inhibitors major cardiovascular events

Below, we summarize key topics and findings from the literature:

Topic	Key Findings
How effective are PCSK9 inhibitors, especially evolocumab, at reducing cardiovascular events?	- Evolocumab significantly reduces LDL cholesterol and the risk of major cardiovascular events in patients with established cardiovascular disease, with consistent effects across subgroups 1 2 12 14. - PCSK9 inhibitors, including evolocumab, lower the incidence of myocardial infarction and stroke, particularly in high- and very-high-risk individuals 13 14 15.
Does intensive LDL-C lowering with or without statins provide additional benefit?	- More-intensive LDL-C lowering (via statins, PCSK9 inhibitors, or ezetimibe) leads to greater reductions in cardiovascular morbidity and is proportional to the magnitude of LDL-C reduction 9 10 14. - PCSK9 inhibitors are most effective for preventing major cardiovascular events, while statins remain most effective for reducing mortality 10 14.
Are there benefits of cholesterol lowering for primary prevention in high-risk patients without established atherosclerosis?	- Statin therapy reduces major cardiovascular events in high-risk patients even with average or lower-than-average cholesterol, suggesting benefit in primary prevention 6 9. - PCSK9 inhibitors have not been widely studied in primary prevention, but this gap is addressed by the current study 13.
What are the safety and comparative effectiveness considerations for cholesterol-lowering therapies?	- Evolocumab and other PCSK9 inhibitors are generally well tolerated, with adverse event rates similar to placebo aside from minor increases in injection-site reactions 1 2 11. - Alirocumab may offer lower all-cause mortality and fewer serious adverse events compared to evolocumab, though evolocumab may be optimal for myocardial infarction prevention 15.

How effective are PCSK9 inhibitors, especially evolocumab, at reducing cardiovascular events?

Numerous randomized controlled trials and meta-analyses have demonstrated that PCSK9 inhibitors, especially evolocumab, substantially lower LDL cholesterol and reduce major adverse cardiovascular events, such as myocardial infarction and stroke, primarily in patients with established cardiovascular disease. The new study extends these findings to a primary prevention population—high-risk diabetic patients without atherosclerosis—showing a 31% risk reduction in first major events, similar in magnitude to prior secondary prevention results.

• Evolocumab led to a median 59–61% reduction in LDL cholesterol and significantly reduced the risk of major cardiovascular events in high-risk patients 1 2.
• The FOURIER trial and related analyses confirmed these benefits across diverse patient populations, with consistent relative risk reductions 1 12.
• PCSK9 inhibitors also reduce the risk of events in those with elevated Lp(a) and high inflammatory risk 3 5.
• In meta-analyses, PCSK9 inhibitors were ranked as the most effective therapy for reducing major adverse cardiovascular events, myocardial infarction, and stroke 14.

Does intensive LDL-C lowering with or without statins provide additional benefit?

The clinical benefit of LDL-C lowering appears directly proportional to the degree of reduction achieved, regardless of whether the therapy is a statin, PCSK9 inhibitor, or another agent. Multiple analyses show that combination or more aggressive lipid-lowering strategies yield further reductions in cardiovascular morbidity, especially in high-risk groups.

• Intensive LDL-C lowering with statins, PCSK9 inhibitors, or ezetimibe reduces major vascular events more than less-intensive regimens 9 10 14.
• The benefit of PCSK9 inhibitors is additive to statin therapy, and the absolute reduction in events is greatest in those at highest baseline risk 10 14.
• Both statins and PCSK9 inhibitors are effective, but PCSK9 inhibitors may provide incremental benefits in very high-risk populations 10 13.
• Achieving very low LDL-C levels with these therapies does not appear to increase adverse events 1 2 11.

Are there benefits of cholesterol lowering for primary prevention in high-risk patients without established atherosclerosis?

While most cholesterol-lowering trials have focused on secondary prevention, some studies show substantial benefit in high-risk patients without established atherosclerosis, particularly those with diabetes or multiple risk factors. The current study provides new evidence for benefit in this group using evolocumab.

• Atorvastatin significantly reduced major cardiovascular events in hypertensive patients with average or lower-than-average cholesterol, supporting cholesterol lowering in primary prevention 6.
• Meta-analyses confirm that LDL-C reduction with statins is associated with a decrease in major vascular events, even in those without manifest cardiovascular disease 9.
• The benefit of PCSK9 inhibitors for primary prevention has been less clear, but the current study helps fill this gap, showing benefit in high-risk diabetic patients without significant atherosclerosis 13.
• The magnitude of benefit is linked to baseline risk; higher-risk individuals derive greater absolute event reductions 10 13.

What are the safety and comparative effectiveness considerations for cholesterol-lowering therapies?

PCSK9 inhibitors, including evolocumab, are generally safe and well tolerated, with most adverse events occurring at similar rates to placebo, aside from minor injection-site reactions. Comparative studies suggest potential differences among PCSK9 inhibitors in terms of mortality and adverse event profiles, but all are effective at reducing cardiovascular events.

• Evolocumab did not increase rates of new-onset diabetes, neurocognitive events, or other major adverse effects compared with placebo 1 2 11.
• Alirocumab may offer a lower risk of all-cause mortality and fewer serious adverse events compared to evolocumab, though evolocumab may be preferred for myocardial infarction prevention 15.
• PCSK9 inhibitors are effective even when added to maximally tolerated statin therapy or in statin-intolerant patients 13.
• Event rates are lowest in patients who achieve both low LDL-C and low inflammatory markers 5.

Future Research Questions

While this study expands the evidence base for intensive cholesterol lowering in primary prevention, several questions remain about the optimal use, long-term outcomes, and broader applicability of PCSK9 inhibitors in diverse populations. Further research is needed to refine prevention strategies and address remaining uncertainties.

Research Question	Relevance
What are the long-term safety and effectiveness of evolocumab in primary prevention populations?	Long-term data are lacking for the use of evolocumab in high-risk groups without established atherosclerosis; existing studies have focused on secondary prevention and shorter follow-up 1 2 13.
How does evolocumab compare to alirocumab and other PCSK9 inhibitors for primary prevention outcomes?	Comparative effectiveness and safety among PCSK9 inhibitors remain uncertain, especially for primary prevention; some analyses suggest differences in mortality and adverse event profiles 15.
What is the cost-effectiveness of early PCSK9 inhibitor therapy in high-risk diabetic patients without atherosclerosis?	The high cost of PCSK9 inhibitors raises questions about their value in primary prevention settings where absolute risk reductions may be lower than in secondary prevention 10 13.
Do the benefits of intensive LDL-C lowering with PCSK9 inhibitors extend to other high-risk groups without atherosclerosis?	Evidence in populations such as those with chronic kidney disease, familial hypercholesterolemia, or inflammatory conditions is limited, and further studies are needed to generalize findings 13 14.
What are the mechanisms underlying the differential effects of PCSK9 inhibitors on myocardial infarction versus stroke risk?	Some studies report greater reductions in myocardial infarction than stroke; understanding the biological mechanisms may help optimize therapy selection 3 12 14.